Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma

Multiple Cancer Types

This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in a class of medications called vinca alkaloids. They work by stopping cancer cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. It works by damaging the cells deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cells DNA and may kill cancer cells. It may also lower the bodys immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are chemotherapy medications that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or for the rest of patients life.
Pediatrics, Sarcoma
III
Borinstein, Scott
NCT04994132
COGARST2031

Hypofractionated Radiotherapy followed by Surgery for the Treatment of Soft Tissue Sarcomas

Sarcoma

This phase II trial studies the effect of hypofractionated radiotherapy followed by surgery in treating patients with soft tissue sarcoma. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving hypofractionated radiotherapy followed by surgery may allow patients with sarcomas to be treated in a much more rapid and convenient fashion.
Sarcoma
II
Shinohara, Eric
NCT04506008
VICCSAR2062

Blood based biomarkers for minimal residual disease detection in Pediatric Sarcomas

Multiple Cancer Types

Pediatrics, Sarcoma
N/A
Borinstein, Scott
VICCPED2160

CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan.

Multiple Cancer Types

Pediatrics, Sarcoma
N/A
Friedman, Debra
VICCPED2222

Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients with Localized Leiomyosarcoma Receiving Chemotherapy

Sarcoma

Sarcoma
N/A
Davis, Elizabeth
NCT04925089
VICCSAR2121

Observational Study of Biomarkers of Disease-related Outcomes in Patients with Metastatic Leiomyosarcoma Receiving Chemotherapy

Sarcoma

Sarcoma
N/A
Davis, Elizabeth
NCT05653388
VICC-ITSAR23169

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.